Michael Morin is praised as a "natural-born leader" and a "talented, extremely clever, hardworking and experienced lawyer" who "you can trust with your crown jewel assets." He has the ability to "stand up in court and present complex subject matter in an even-handed, compelling way." One client notes "the litigation profession is becoming increasingly uncivil, so it’s great when you get to deal with someone like Mike."IAM Patent 1000 2016-2019

Michael A. Morin

Washington, D.C. | Chicago
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA

Michael Morin is a partner in the Washington, D.C. office of Latham & Watkins and Global Vice Chair of the Intellectual Property (IP) Litigation Practice. Mr. Morin is an accomplished trial lawyer who has been litigating complex and high-profile patent cases for more than two decades. He has secured many victories for his clients at every stage in the process: in district court, in arbitration, at the PTAB, and on appeal.

While Mr. Morin handles cases in a wide array of subjects, he has deep experience in pharmaceutical matters, where he has been lead counsel for some of the world’s top pharmaceutical companies, on some of the world’s best-selling drugs. He has led multiple litigations under the new Biosimilars Act, and regularly handles “brand on brand” litigations between innovative pharmaceutical companies. He also leads ANDA litigations between innovators and generics.

Mr. Morin also has extensive experience litigating medical device cases, involving stents, catheters, guidewires, grafts, filters, ICD’s, and pacemakers, among others.

In addition, Mr. Morin has successfully litigated cases involving software, electronics, consumer products, industrial equipment, sporting goods, and amusement rides.

Mr. Morin is frequently involved in contested Patent Office proceedings, often in parallel with litigations he is handling. He has substantial experience coordinating global litigation strategy, overseeing proceedings in the EPO, the UK, Germany, France, the Netherlands, Ireland, Canada, and Japan, among others. He also advises clients regarding their intellectual property portfolios and strategies, assists with licensing issues, and provides other IP advice.

Mr. Morin is recognized as a leading IP litigation lawyer by numerous industry publications. He is recognized for his work across the life sciences industry and was recommended by The Legal 500 US 2017 – 2018 and named a Life Sciences Star for IP litigation by Legal Media Group and Euromoney 2016 – 2019. He is repeatedly recognized in Intellectual Asset Management’s Patent 1000 – The World’s Leading Patent Practitioners guide 2015 – 2019, with clients praising him for maintaining “excellent command of his team” and having a “real presence in the courtroom.” He also “does a terrific job of breaking down the technology.” He is also recommended by Who’s Who Legal – Patents and Life Sciences - Patent Litigation, 2016 – 2019. In 2019, Managing Intellectual Property named him an IP Star and shortlisted him for Outstanding Litigator: District of Columbia. Also, Mr. Morin has been honored as a Life Sciences Star and was shortlisted for General Patent Litigator of the Year: District of Columbia by LMG Life Sciences in both 2018 and 2019.

In addition, Mr. Morin devotes considerable time to pro bono activities, representing low-income tenants and disabled veterans in civil matters and indigent defendants in criminal cases. He previously served on the firm’s Recruiting Committee, and was in charge of recruiting for the global IP group.

Mr. Morin is a faculty member of the Trial Advocacy College at the University of Virginia, where he teaches trial skills to lawyers from around the United States. He is heavily involved in the Sedona Conference, where he leads a working group on parallel district court and PTO proceedings. He frequently lectures on litigation matters at conferences hosted by the Federal Circuit Bench and Bar, the American Bar Association, the American Conference Institute, the American Intellectual Property Law Association, the American Law Institute-American Bar Association, the Patent Resource Group, and the Practising Law Institute.

Mr. Morin’s representative experience includes serving as lead counsel for:

  • AbbVie in numerous litigations involving Humira®, the world’s best-selling drug, resulting in multiple trial, arbitration, and appellate wins*
  • AbbVie in litigations involving numerous other innovative drugs, including Viekira®, Zemplar®, and Imbruvica®, among others*
  • Abbott in litigation involving numerous innovative medical device products, resulting in multiple trial, arbitration, and appellate wins, as well as a US$400 million settlement involving coronary stents*
  • Janssen (a Johnson & Johnson company) in litigation involving its innovative Darzalex® product
  • St. Jude Medical in litigation involving its class-leading electrophysiology products
  • Intellia Therapeutics in multiple matters relating to CRISPR/Cas9 gene-editing technology
  • Neurocrine in litigation involving its innovative Elagolix® product
  • Quest Integrity in appeals involving furnace inspection technology
  • 3M in multiple litigation matters, including a case involving its market-leading painter’s tape, a case involving combat helmets, and a case involving adhesive bandages*
  • SAP in multiple patent infringement cases involving its market-leading business software*

*At least some of these matters were handled prior to Mr. Morin joining Latham

Thought Leadership
  • Chapter Editor, “The Sedona Conference Commentary on Patent Litigation Best Practices: Parallel USPTO Proceedings,” (2014 – 2017) (multiple editions)
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.